

DEC 17 2004

K043077

1.62

TORNIER

Implants Chirurgicaux

Summary of Safety and Effectiveness information Premarket notification 510(k) – AEQUALIS Shoulder

Regulatory authority: Safe Medical Devices Act of 1990, 21 CFR 807.92

1) Device name

Trade name: *AEQUALIS Shoulder Fracture System*
AEQUALIS Shoulder System
Common name: Total-Shoulder System and Hemi-Shoulder System
Classification name: Shoulder joint metal/polymer semi-constrained cemented prosthesis

2) Submitter

Tornier S.A.
B.P. 11 - Rue Doyen Gosse
38330 Saint Ismier - France

3) Company contact

Tornier S.A.
Mrs Mireille Lémery
Regulatory affairs & Quality Engineer
ZIRST - 161, rue Lavoisier
38330 Montbonnot - France
Tel: 00 33 4 76 61 38 98
Fax: 00 33 4 76 61 35 33
e-mail : mireille.lcmery@tornier.fr

4) Classification

Device class: Class II
Classification panel: Orthopedic
Product code: KWS
§ 888.3660 Shoulder joint metal/polymer semi-constrained cemented prosthesis.

5) Equivalent / Predicate device

For the AEQUALIS Shoulder Fracture System:

AEQUALIS Shoulder system, TORNIER SA, K952928, K041339
AEQUALIS Shoulder Fracture system, TORNIER SA, K994392, K003728, K032679
Modular Shoulder System, Wright Medical Technology Inc, K002683
Select Shoulder System, Intermedics Orthopedics, K873679

Page 1/ page 2



TORNIER S.A
161, rue Lavoisier
38330 MONTBONNOT
FRANCE

Tél. : 33 (0)4 76 61 35 00
Fax : 33 (0)4 76 61 35 33

S.A. au capital de 1 800 000 F
SIRET : 070 501 275 000 13
R.C.S. : B 070 501 275
CODE APE : 331 B

SIEGE SOCIAL : B.P. 11 - rue du Doyen Gosse - 38330 SAINT-ISMIER - FRANCE



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

DEC 17 2004

Ms. Lemery Mireille
Regulatory Affairs & Quality Engineer
Tornier S.A.
161 rue Lavoisier
38330 Montbonnot
France

Re: K043077

Trade/Device Name: Aequalis Shoulder Fracture system, Aequalis Shoulder System
Regulation Name: 21 CFR 888.3660 Shoulder join metal/polymer semi-constrained
cemented prosthesis

Regulatory Class: II

Product Code: KWS

Dated: November 4, 2004

Received: November 16, 2004

Dear Ms. Lemery:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Kathy A. Racosky

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0210. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "for Celia M. Witten". The signature is written in a cursive style and is positioned to the left of the typed name.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

107

K043077

Indications statement

510(k) Number (if known):

Device Name: *Aequalis Shoulder Fracture System*
Aequalis Shoulder System

Indications For Use:

AEQUALIS Shoulder Range (except AEQUALIS for Fracture):

Prosthetic replacement with this device may be indicated to relieve severe pain or significant disability caused by:

- Degenerative pathologies : arthrosis, rheumatoid arthritis, post-traumatic arthrosis. Primary and secondary necrosis of the humeral head
- Displaced 4-part upper humeral fracture
- Humeral head fracture
- Other pathologies where arthrodesis or resectional arthroplasty of the humeral head are not acceptable
- Revision surgery when other treatments or devices have failed.

AEQUALIS for Fracture:

Traumatic or pathologic conditions of the shoulder resulting in fracture of the glenohumeral joint, including humeral head fracture and displaced 3-or 4-part proximal humeral fractures.

Revision surgery when other treatments or devices have failed.

Prescription Use
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use _____
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)


Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
**Division of General Restorative,
and Neurological Devices**

510(k) Number K043077